Non-invasive in vivo assessment of IDH1 mutational status in glioma
Myriam M. Chaumeil(University of California System), Sabrina M. Ronen(University of California, San Francisco)
Cited by 142
Related Papers
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
|Scientific Reports|2019|64
17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2
|Breast Cancer Research|2010|31